知镜 Cognispect · 医学文献与研究工作台

CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease.

Cao Y, Sun X, Huang Y, Chen C, Ji B, Chen R, Li Y, Liang Y, Aghevli A, Yang N, Patel V, Harris P, Ling K, Hu J, He K.
Journal of the American Society of Nephrology : JASN · 2026-09-14 · PMID 42735034

文献摘要

Key points CDK6 was robustly upregulated in cyst-lining epithelial cells. The CDK4/6 inhibitor abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin dosage in autosomal dominant polycystic kidney disease renal epithelial cells. Abemaciclib arrested or reversed cyst progression in a sex-specific manner with greater efficacy and safety than tolvaptan in an autosomal dominant polycystic kidney disease mouse model. Background Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disorder leading to kidney failure. Tolvaptan, the only US Food and Drug Administration-approved therapy, modestly slows disease progression but is limited by significant adverse effects, highlighting the need for more effective and better-tolerated treatments. Ciliary polycystins are central to ADPKD pathogenesis. We previously demonstrated that a ciliary base-localized pool of CDK6 restricts ciliary polycystin abundance by suppressing axonemal polyglutamylation. However, whether CDK6 inhibition can restore polycystin function and suppress ADPKD progression in vivo remains unknown. Methods Abemaciclib was tested in in vitro 3D cyst assays and ex vivo metanephric organ cultures. In vivo efficacies of early- and late-stage intervention were assessed in F1(129/B6) Pkd1R3277C/R3277C mice receiving daily abemaciclib. Tolvaptan served as a therapeutic control. Cyst burden, fibrosis in the kidneys, kidney function, and primary cilia of renal epithelial cells were analyzed at study end points. Results CDK6 was prominently upregulated in cyst-lining cells in human and murine polycystic kidney disease kidneys. At doses substantially lower than those used in oncology, abemaciclib robustly suppressed cyst growth in vitro and ex vivo . In vivo , long-term early treatment arrested cyst progression more effectively than tolvaptan without detectable toxicity. Late intervention largely halted cyst growth in female mice and reversed cyst progression in male mice. Mechanistically, abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin levels. Conclusions Abemaciclib had greater therapeutic efficacy and tolerability than tolvaptan in this preclinical model, largely driven by CDK6 inhibition-mediated restoration of axonemal polyglutamylation and increased ciliary polycystin abundance.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。